IRRAS USA Inc.

Pssssst -  Something new is coming to the IRRAflow system... stay tuned for more. Ask us about the next generation of IRRAflow – reach out to our team at https://lnkd.in/e7H4TmSk!

We are proud to join the global conversation on #WorldHealthDay and #NationalPublicHealthWeek. As pioneers in Active Fluid Exchange, we are deeply committed to improving public health and advancing healthcare solutions that make a real difference. This week serves as a reminder of the vital importance of access to quality healthcare for all. From innovative technologies to thoughtful partnerships, we’re dedicated to pushing the boundaries of what’s possible. We believe in the power of collaboration, innovation and advocacy to create a healthier future for everyone. Together, let’s continue to pave the way toward better health outcomes and a brighter future for public health across the globe. 

With a new quarter comes a new Employee Spotlight!    Meet Courtney, Staff Accountant at IRRAS.    “IRRAS is special – our mission and our story are unique. Usually in accounting, we tend to work behind the scenes and aren’t heavily involved in the day-to-day operations. At IRRAS, the team is consistently sharing amazing news about patient recovery with our technology. This has made myself and my colleagues feel like we are a part of something greater. I can honestly say that it’s inspiring to hear about all the good that IRRAS does.”    We truly appreciate your hard work and dedication. Thank you for all you contribute! 

In the spirit of Healthcare Thought Leadership and Innovation Month, we’re reflecting on home-run cases like the one below: Active Cerebrospinal Fluid Exchange proved to be a promising treatment for pyogenic ventriculitis at Helsinki University Central Hospital in Helsinki, Finland.    The computed tomography images below demonstrate the clearing of bacterial mass with IRRAflow and antibiotics. This 58-year-old female patient had an atrial shunt placed in childhood and was admitted due to staphylococcus aureus sepsis, thrombovegetation of the heart and shunt infection. Intravenous cloxacillin antibiotic therapy and EVD insertion led to expanded bacterial growth and intubation, leading the physician to initiate IRRAflow irrigation with NaCl 0.9% at 180 mL/hour. Gentamycin was delivered as a daily bolus intrathecally at 9 mg/day using 21 L of saline.    The patient was discharged after 37 days of therapy. During a 2.5 year follow-up, there were no new central nervous system infections present.    In Partnership With Helsinki University Central Hospital. Corresponding Author: Behnam Rezai Jahromi, MD, Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland. 

Stroke care is evolving, and #IRRAflow is leading the way. By providing active fluid exchange, continuous ICP monitoring and superior drainage, IRRAflow significantly improves outcomes for patients suffering from hemorrhagic strokes. With the ability to reduce complications and shorten treatment times, IRRAflow is changing how stroke patients are managed in the ICU. Explore the benefits of IRRAflow at www.irraflow.com. 

“Using IRRAflow is a giant leap forward in fluid management,” says Dr. Sumeet Vadera. “Rather than just draining the blood, IRRAflow has a pump that gives it an irrigating component, and you can actually see the blood getting washed out.” - Sumeet Vadera, MD, MBA, FAANS, Director of Epilepsy Surgery, Associate Program Director of Neurological Surgery     The result, according to Vadera, is a significantly reduced risk of clot recurrence and a reduction in treatment time. 

We are pleased to announce an enrollment milestone in the Active Removal of IntraCerebral Hematoma via active irrigation of ventricular system (ARCH) clinical trial. The prospective, randomized, international and multicenter investigator-initiated trial has enrolled its 30th patient, enroute to 60 patients total. This milestone marks a significant step in advancing research that aims to improve outcomes in Hemorrhagic Stroke.    Led by Principal Investigator Behnam Rezai Jahromi, MD, PhD, Neurocenter, division of Neurosurgery, University of Helsinki, the study will assess the effectiveness of active irrigation by IRRAflow with infusion of Tissue Plasminogen Activator (tPA) compared to traditional therapy. This trial has reached this milestone as scheduled, underscoring the strong interest and engagement from the clinical trial partners. The enrolling clinical trial sites include:    University of Helsinki Stony Brook University   Northwestern Medicine   Mount Sinai Health System Buffalo General Medical Center     “We are excited to have reached this key milestone, bringing us closer to uncovering critical insights that could benefit patients worldwide,” said Dr. Behnam Rezai Jahromi. “We believe that the combination of active CSF Exchange with tPA has the potential to be vastly more efficient in removing hemorrhage. Our goal is to expand scientific understanding and explore new possibilities for improving patient care.”    Enrollment continues as the sites work toward completing patient recruitment and moving forward with the next phase of the study. The findings from this trial could have a significant impact on managing intracerebral hemorrhage, potentially leading to new treatment strategies and improved patient outcomes.    For more information about the ARCH Clinical trial, visit Clinicaltrials.gov. 

March is Brain Injury Awareness Month, a crucial opportunity to highlight the impact of brain injuries on individuals and their families. Join us as we continue to educate, raise awareness and foster a deeper understanding of brain injuries and the path to recovery. 

The multidisciplinary symposium bringing together national and regional experts on intracerebral hemorrhage is TOMORROW at the Northwestern Medicine ICH Workshop!    This event is a golden opportunity to discover more about the interim results of the ARCH Trial, experience invaluable hands-on workshops and participate in debates and discussions surrounding state-of-the-art neurointensive care for patients with ICH.    Schedule time with an IRRAS team member at the link below: https://lnkd.in/gPmicjYS